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DOI 10.1016/j.ccr.2010.04.025SUMMARYAlthough Bcr-Abl kinase inhibitors have proven effective in the treatment of chronic myeloid leukemia (CML),
they generally fail to eradicate Bcr-Abl+ leukemia cells. To identify genes whose inhibition sensitizes Bcr-Abl+
leukemias to killing by Bcr-Abl inhibitors, we performed an RNAi-based synthetic lethal screen with imatinib
mesylate in CML cells. This screen identified numerous components of a Wnt/Ca2+/NFAT signaling pathway.
Antagonism of this pathway led to impaired NFAT activity, decreased cytokine production, and enhanced
sensitivity to Bcr-Abl inhibition. Furthermore, NFAT inhibition with cyclosporin A facilitated leukemia cell
elimination by the Bcr-Abl inhibitor dasatinib and markedly improved survival in a mouse model of Bcr-
Abl+ acute lymphoblastic leukemia (ALL). Targeting this pathway in combination with Bcr-Abl inhibition could
improve treatment of Bcr-Abl+ leukemias.INTRODUCTION
CML is a myeloproliferative disorder characterized by a t(9;22)
translocation, which gives rise to a shortened chromosome 22,
the Philadelphia chromosome (Ph). This translocation results in
a fusion between the genes encoding the Abl tyrosine kinase
and Bcr. The resultant protein, Bcr-Abl, has constitutive tyrosine
kinase activity and is considered causative in the disease
(Deininger et al., 2000). Ph is also found in 20%–30% of ALL
and is associated with poor prognosis (Faderl et al., 2002).
Bcr-Abl activates a number of downstream targets including
Ras, PI3 kinase, NF-kB, and STAT5, resulting in cytokine-inde-Significance
The promise of targeted cancer therapies has generated much
ment of chronic phase CML. However, targeted therapies f
responses. For example, patients with advanced phase CML
Abl inhibitors. The targeting of additional genes may be nec
RNAi-based screen described here identified numerous comp
tizes leukemic cells to Bcr-Abl inhibitors. Pharmacological targe
leukemias. Our screen may also serve as a model for discover
74 Cancer Cell 18, 74–87, July 13, 2010 ª2010 Elsevier Inc.pendent growth, resistance to apoptosis, and altered cellular
adhesion (Sattler and Griffin, 2003).
Imatinib mesylate is a tyrosine kinase inhibitor that blocks the
activity of Bcr-Abl and induces remarkable hematological and
cytogenetic responses in chronic phase CML patients (Deininger
et al., 2005). Although imatinib is a highly effective treatment for
CML, it is rarely curative. Cessation of imatinib therapy can result
in relapse of the disease even in patients that show a complete
response (Rousselot et al., 2007). Furthermore, a significant
number of chronic phase patients on imatinib therapy eventually
relapse (16% within 42 months; (Deininger et al., 2005). Relapse
is often associated with mutation of Bcr-Abl. Another majorexcitement with the success of Bcr-Abl inhibitors for treat-
or other cancers have typically failed to achieve durable
and Bcr-Abl+ ALL do not show long-term responses to Bcr-
essary to enhance the efficacy of Bcr-Abl inhibitors. The
onents of a Wnt/Ca2+/NFAT pathway whose inhibition sensi-
ting of this pathway could improve the treatment of Bcr-Abl+
y of adjuvant targeted therapies for other forms of cancer.
Figure 1. Knockdown of FZD-8 Sensitizes CML Cells to Imatinib and Impairs NFAT Activity
(A) Diagrammatic representation of the Wnt/Ca2+/NFAT pathway. Pathway details are described in the text.
(B) K562 CML cells were stably transduced with shRNAs (shA or shB) targeting FZD-8 or a negative control shRNA. Real-time PCR (qPCR) was performed on
resultant cell lines to examine FZD-8 expression levels normalized to 18S ribosomal RNA.
(C) K562 cell lines were left untreated or treated with imatinib at 0.1 mM for 72 hr, after which the cells were reseeded in the absence of drug and cultured for an
additional 4 days. The number of viable cells (based on PI exclusion) was counted by flow cytometry at the indicated time points.
(D) K562 cell lines were infected with an adenoviral NFAT-luciferase reporter. After 32 hr, the cells were left untreated or treated with ionomycin at 1 mg/ml for 16 hr
after which the cells were harvested and luciferase activity was assayed. Error bars represent ± SD. See also Figure S2.
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more refractory than chronic phase CML to imatinib therapy.
Only 15% of patients in CML blast crisis and 29% of Ph+ ALL
patients achieve a complete hematological response, and
a majority of these relapse within a few months (Deininger
et al., 2005; Ottmann et al., 2002). Advanced phase CML
patients and those with Ph+ ALL also fail to achieve durable
remissions with the more potent second-generation Bcr-Abl
inhibitors nilotinib and dasatinib (Quintas-Cardama et al.,
2007). These findings underscore the need to identify targets
that will cooperate with Bcr-Abl inhibition to more effectively
treat CML and Ph+ ALL and hopefully eradicate these diseases.
Wnt family members are secreted proteins that signal through
the frizzled superfamily of G protein-coupled receptors. Activa-
tion of the canonical Wnt signaling pathway leads to nuclear
accumulation of the Lef-Tcf transcriptional coactivator b-catenin
(Cadigan and Liu, 2006). In addition, two noncanonical Wnt path-ways have been identified that signal independently of b-catenin:
the planar cell polarity pathway and the Ca2+/NFAT pathway
(Veeman et al., 2003). In the Wnt/Ca2+/NFAT pathway
(Figure 1A), Wnt5a-bound Frizzled (FZD), in association with
a noncanonical coreceptor such as Ryk, acts through G proteins
to activate phospholipase C (PLC) and phosphodiesterase (PDE)
(Ahumada et al., 2002; Sheldahl et al., 2003; Slusarski et al.,
1997). Activation of PLC initiates hydrolysis of membrane-bound
lipid, generating two secondary messengers, diacylglycerol
(DAG) and inositol-1,4,5-triphosphate (IP3). DAG stimulates
protein kinase C (PKC), whereas IP3 promotes the release of
intracellular Ca2+. Increased concentrations of Ca2+ lead to acti-
vation of the Ca2+-sensitive proteins Ca2+-calmodulin-depen-
dent protein kinase II (CaMKII; Kuhl et al., 2000) and the Ca2+-
calmodulin-dependent protein phosphatase calcineurin and
its target, the transcription factor NFAT (Saneyoshi et al.,
2002). Dephosphorylation of NFAT by calcineurin promotes itsCancer Cell 18, 74–87, July 13, 2010 ª2010 Elsevier Inc. 75
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tion of cytokine genes such as interleukin-4 (IL-4; Hogan et al.,
2003). A role for the Wnt/Ca2+/NFAT pathway in leukemia cells
is unclear.
The purpose of this study was to identify pathways that can be
targeted to more effectively eliminate Ph+ leukemia cells in
combination with Bcr-Abl inhibition.
RESULTS
RNAi-Based Screen Identifies Wnt/Ca2+/NFAT Pathway
Genes as Synthetic Lethal with Imatinib
In order to identify genes and pathways whose inhibition sensi-
tizes CML cells to killing by imatinib, we performed a large-scale
RNAi-based synthetic lethal screen. A lentiviral shRNA library
was utilized that contains 3–5 shRNAs per target gene for
50,000 different human transcripts. This library was trans-
duced into K562 CML cells and the cells were selected in puro-
mycin for 2 weeks to obtain a pure population of transduced cells
and allow for the exclusion of shRNAs that target essential
genes. The transduced cells were either left untreated or treated
with imatinib at 1 mM for 72 hr, a dose that eliminated approxi-
mately 85% of the cells. The cells were cultured for an additional
week, and total RNA was then isolated, reverse-transcribed, and
the shRNA sequences were polymerase chain reaction (PCR)
amplified and labeled with biotin. Biotin-labeled PCR products
were used to probe Affymetrix microarrays to assess represen-
tation of individual shRNAs. Although few shRNAs provided
resistance, a number of shRNAs were deleterious to K562 cells
upon exposure to imatinib (see Figure S1A available online).
Our screen identified 145 genes (Table S1) that met the following
three criteria: (1) shRNAs targeting the gene were underrepre-
sented > 6-fold in imatinib treated cells compared with untreated
cells inR 2/3 of comparisons; (2) the observed differences had
a p value of < 0.05; and (3) at least two unique shRNAs per target
gene were identified, minimizing identification of false positives
due to off-target effects. We have dubbed these genes ‘‘SLIMs’’
(for synthetic lethal with imatinib mesylate). The SLIMs fall into
functional categories that include cell attachment, inflammatory
signaling, cell migration, hematological system development,
and hematopoietic cell proliferation and differentiation (Fig-
ure S1B and Table S2).
Among the SLIMs, the Wnt receptor FZD-8 was identified by
three different shRNAs, each underrepresented > 116-fold in
imatinib-treated cells. FZD-8 is a poorly characterized Wnt
receptor whose signaling in mammalian cells remains largely
unstudied. Components of the canonical Wnt/b-catenin pathway
signaling were not identified; however, isoforms of both CaMKII
(b) and PKC (q), which are known to participate in the noncanon-
ical Wnt/Ca2+/NFAT pathway, were identified. When the screen
criteria were loosened to include genes that were identified by
single shRNAs, canonical Wnt pathway components were still
not found. Conversely, numerous potential components of the
Wnt/Ca2+/NFAT signaling pathway were additionally identified
(Table 1). These include the noncanonical ligand Wnt5a, FZD-2
(Ahumada et al., 2002), the noncanonical FZD coreceptor Ryk
(Kim et al., 2008), p38b MAPK, PDE6C, and H, PLCb, CaMKIIg
and its substrate RARa (Si et al., 2007), calcineurin A (a and b),
NFATc1, and its target genes IL-4 (Guo et al., 2008) and CCL2376 Cancer Cell 18, 74–87, July 13, 2010 ª2010 Elsevier Inc.(Shin et al., 2007). This list also includes several genes that,
although not known to be involved in noncanonical Wnt signaling,
are known or suspected to influence NFAT-dependent transcrip-
tion: IL-7, RCAN1, NFATC2IP, Fra-1, EGR3, and PRMT8 (Boise
et al., 1993; Gringhuis et al., 1997; Hodge et al., 1996; Liu et al.,
2009; Mowen et al., 2004; Rengarajan et al., 2000). Thus,
screening results suggest a role for Wnt/Ca2+/NFAT in maintain-
ing CML survival in the face of Bcr-Abl inhibition.
Inhibiting the Wnt/Ca2+/NFAT Pathway Sensitizes Ph+
Leukemia Cells to Killing by Bcr-Abl Inhibitors
To verify that knockdown of the FZD-8 receptor sensitizes CML
cells to imatinib, we stably transduced two different lentiviral
constructs expressing shRNAs targeting FZD-8 (shA and shB)
into K562 cells. Analysis of FZD-8 expression using real-time
PCR revealed that shB significantly reduced FZD-8 expression
(50%) relative to a control non-targeting shRNA, whereas
shA failed to significantly reduce expression (Figure 1B), and
thus shA serves as an additional negative control. shB did not
have a substantial impact on the proliferation rate of K562 cells
(Figure S2A), indicating that FZD-8 knockdown does not affect
cell viability in the absence of imatinib. For examining the conse-
quences of imatinib treatment, these cell lines were exposed to
0.1 mM imatinib for 72 hr and the number of viable cells, based
on propidium iodide (PI) exclusion, was determined with flow
cytometry. The cells were then reseeded in the absence of
drug and viability was monitored over 7 days. Figure 1C shows
that shB-expressing cells were severely sensitized to imatinib-
mediated killing relative to untransduced and control cells. This
translated into a dramatic effect on long-term viability: whereas
the control cells recovered from imatinib treatment and were
proliferating normally by day 7, the shB cells did not significantly
recover. These results suggest that even partial FZD-8 knock-
down can significantly potentiate the efficacy of imatinib in killing
CML cells.
FZD-8 is a largely unstudied Wnt receptor whose role in acti-
vating noncanonical Wnt/Ca2+/NFAT signaling has not been
examined. Frizzled receptors are known to transduce signals
that lead to activation of b-catenin, and knockdown of b-catenin
has previously been shown to sensitize CML cells to imatinib
(Coluccia et al., 2007). Indeed, we also found that b-catenin
knockdown decreased viability of K562 CML cells treated with
imatinib, although not nearly to the same extent as knockdown
of FZD-8 (Figure S2). Moreover, knockdown of FZD-8 did not
affect levels of b-catenin protein in the nucleus or its transcrip-
tional activity (Figure S2), inconsistent with a role for FZD-8 in
signaling through the canonical pathway. Given that so many
potential mediators of Wnt/Ca2+/NFAT signaling were identified
in the screen, we wanted to determine whether knockdown of
FZD-8 altered the activity of NFAT. Therefore, K562 cells
expressing shA, shB, or control shRNA were transduced with
an NFAT reporter construct that contains tandem NFAT binding
sites derived from the IL-4 promoter fused to luciferase (Braz
et al., 2003). Luciferase activity was severely impaired in shB
cells relative to control cells (Figure 1D), and this was rescued
by treatment with the calcium ionophore ionomycin suggesting
that FZD-8 acts upstream of intracellular Ca2+ release, consis-
tent with a role for FZD-8 in mediating Wnt/Ca2+/NFAT pathway
signaling.
Table 1. Potential Wnt/Ca2+/NFAT Pathway Genes Identified as SLIMs
RefSeq ID Mean FC Hgnc Symbol Description Number of ShRNAs
NM_005438 183.41 FOSL1 Fos-related antigen 1 (Fra-1) 1
NM_006257 154.91 PRKCQ Protein kinase C theta type 2
NM_031866 146.08 FZD8 Frizzled-8 precursor 3
NM_172084 133.08 CAMK2B Calcium/calmodulin-dependent protein kinase type II beta 2
NM_004430 131.92 EGR3 Early growth response protein 3 2
NM_000589 106.66 IL4 Interleukin-4 precursor 2
NM_002751 54.56 MAPK11 Mitogen-activated protein kinase 11 (p38 beta MAPK) 1
NM_006924 45.85 SFRP4 Secreted frizzled-related protein 4 precursor 1
NM_000880 45.53 IL7 Interleukin-7 precursor 1
NM_000964 44.96 RARA Retinoic acid receptor alpha 2
NM_021132 34.12 PPP3CB Calmodulin-dependent calcineurin A subunit beta 1
NM_182734 31.48 PLCB1 Phospholipase C- beta-1 1
NM_006888 31.30 CALM1 Calmodulin (CaM) 2
NM_006204 30.17 PDE6C cGMP phosphodiesterase 6C 1
NM_003392 24.94 WNT5A Wingless-type MMTV integration site family, member 5A 1
NM_005064 22.99 CCL23 C-C motif chemokine 23 precursor 2
NM_005822 22.81 RCAN2 Calcipressin-2 (regulator of calcineurin 2) 1
NM_172387 19.10 NFATC1 Nuclear factor of activated T cells, cytoplasmic 1 1
NM_002958 16.78 RYK RYK receptor-like tyrosine kinase 1
NM_019854 15.79 PRMT8 Protein arginine N-methyltransferase 8 1
NM_006205 14.95 PDE6H cGMP phosphodiesterase 6H 1
NM_004414 13.32 RCAN1 Calcipressin-1 (regulator of calcineurin 1) 1
NM_001466 12.21 FZD2 Frizzled-2 precursor 1
NM_001222 12.18 CAMK2G Calcium/calmodulin-dependent protein kinase type II gamma 1
NM_032815 12.15 NFATC2IP NFATc2-interacting protein 1
NM_000944 11.77 PPP3CA Calmodulin-dependent calcineurin A subunit alpha isoform 1
Genes are listed in ascending order based on the fold-change of corresponding shRNAs. For genes identified by more than one shRNA, the most nega-
tive fold change is shown. See also Tables S1 and S2 and Figure S1.
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examined whether inhibition of CaMKII activity with the CaMKII-
specific inhibitor KN93 could sensitize CML cells to the effects of
imatinib. After 48 hr, the number of viable cells was counted by
flow cytometry (Figures 2A and 2B). Although KN93 had some
effect on cell viability by itself, at 5 and 10 mM it showed a syner-
gistic effect with imatinib in cell elimination (combination index
[CI] values are shown in Table S3). Remarkably, the combination
of 0.1 or 1 mM imatinib and 10 mM KN93 resulted in near complete
cell death. KN93 is known to have off-target effects including the
inhibition of calcium and potassium channels (Gao et al., 2006;
Rezazadeh et al., 2006). However, KN92, an analog of KN93
that retains these off-target effects but is inactive toward
CaMKII, was ineffective in combination with imatinib (Figure S3),
suggesting that the observed synergism with KN93 is due to
CaMKII inhibition. To verify that synergism with KN93 extends
to other Bcr-Abl inhibitors, we demonstrated that KN93 effec-
tively synergized with dasatinib in eliminating K562 cells (Fig-
ure 2C). Although CaMKII is known to participate in Wnt/Ca2+
signaling, CaMKII involvement in regulation of NFAT-dependent
transcription has not been established. Thus, K562 cells
transduced with the NFAT-luciferase reporter were treated with
KN93 for 16 hr and luciferase activity was assayed. KN93 treat-ment caused a dose-dependent reduction in NFAT reporter
activity (Figure 2D), especially in the context of ionomycin-stim-
ulated cells (6- to 7-fold inhibition), consistent with CaMKII acting
downstream of intracellular calcium release.
Given that our results demonstrated a compelling correlation
between impaired NFAT activity and sensitivity of CML cells to
Bcr-Abl inhibition, we next focused on calcineurin, an essential
regulator of NFAT whose activity is required for the nuclear trans-
location of NFAT. Calcineurin is an attractive therapeutic target
because its activity can be effectively inhibited by both tacroli-
mus and cyclosporin A (CsA), two drugs that have been in clinical
use for many years as immunosuppressants. We first utilized
K562 cells to determine if calcineurin inhibition by CsA enhances
CML cell killing by imatinib. K562 cells were treated with combi-
nations of CsA and imatinib for 72 hr. The doses of CsA tested
(1–5 mM) are clinically relevant because patients achieve peak
serum concentrations between 1 and 2 mM with a standard
dosing of CsA used as an immunosuppressant for organ trans-
plantation (Halloran et al., 1999). Although CsA treatment alone
had only a moderate effect on cell number, a dramatic effect
on viability was obvious upon combined treatment with CsA
and imatinib, with 2.5 and 5 mM CsA causing near complete
cell death when combined with either 0.1 or 1 mM imatinibCancer Cell 18, 74–87, July 13, 2010 ª2010 Elsevier Inc. 77
Figure 2. Inhibition of CaMKII Sensitizes CML Cells to Bcr-Abl Inhibition and Impairs NFAT Activity
(A and B) K562 cells were treated with imatinib and KN93 alone or in combination as indicated (increasing KN93 concentrations of 0, 2, 5, and 10 mM are indicated
by the triangles) for 48 hr and viable cells (based on PI exclusion) were counted by flow cytometry (A). Values were normalized to untreated (control) cells and
graphed. Representative flow profiles (side scatter versus forward scatter) from these experiments are shown in (B). The ‘‘cell’’ gate was defined based on
the scatter profile of untreated viable K562 cells (upper left panel). PI+ cells are colored in red and PI in violet.
(C) K562 cells were treated with dasatinib and KN93 as in (A) for 48 hr and viable cells were counted.
(D) K562 cells were infected with an NFAT-luciferase reporter. After 32 hr, the cells were treated with the indicated concentrations of KN93 alone or together with
ionomycin at 1 mg/ml for 16 hr after which cells were harvested and assayed for luciferase activity. Error bars represent ± SD. See also Figure S3.
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flow profiles in Figure S4A). The mechanism by which CsA
enhances imatinib-mediated cell death appears to be by
enhancement of apoptosis, as indicated by a dramatic increase
in sub-G1 DNA content when the two drugs were combined
(Figure S4B). CsA also sensitized K562 cells to the Bcr-Abl inhib-
itor dasatinib (Figure 3B), and thus, as with KN93, the effects of
CsA are not unique to imatinib. Reporter assays verified that CsA
caused a dose-dependent decrease in NFAT-driven transcrip-
tion in both unstimulated and ionomycin-stimulated K562 cells
(Figure 3C). Importantly, imatinib had no influence on NFAT
activity in these cells (Figure S4C). These results suggest that
calcineurin inhibition cooperates with Bcr-Abl inhibition to elimi-
nate CML cells.
In addition to calcineurin, CsA is also known to inhibit p-glyco-
protein (MDR1), a drug efflux pump that has been proposed to78 Cancer Cell 18, 74–87, July 13, 2010 ª2010 Elsevier Inc.contribute to imatinib-resistance in CML (Illmer et al., 2004).
Thus, the effect of CsA, or perhaps even KN93, could potentially
be due to prevention of imatinib efflux from cells, leading to
improved Bcr-Abl inhibition. To examine this possibility, we
treated K562 cells with imatinib and CsA or KN93, alone or in
combination, for 24 hr and subjected them to western blot anal-
ysis for tyrosine-phosphorylated forms of known Bcr-Abl
substrates including CrkL, STAT5, and Bcr-Abl itself, in addition
to global tyrosine phosphorylation. Imatinib effectively inhibited
tyrosine phosphorylation of all examined Bcr-Abl substrates
(Figure 3D) to varying degrees, and global tyrosine phosphoryla-
tion was also affected. However, cotreatment with CsA or KN93
did not enhance this inhibition, inconsistent with roles for CsA or
KN93 in increasing intracellular imatinib concentrations. Further-
more, qPCR analysis failed to detect expression of MDR1 in
K562 cells, whereas its expression was easily detectable in
Figure 3. Inhibition of Calcineurin-NFAT by CsA Sensitizes Ph+ Leukemia Cells to Bcr-Abl Inhibition
(A) K562 cells were treated with imatinib and CsA alone or in combination as indicated (increasing CsA concentrations of 0, 1, 2.5, and 5 mM are indicated by the
triangles) for 72 hr and viable cells were counted by flow cytometry.
(B) K562 cells were treated with dasatinib and CsA as in (A) for 48 hr and viable cells were counted.
(C) K562 cells were infected with an NFAT-luciferase reporter. After 32 hr, the cells were treated with the indicated concentrations of CsA alone or together with
ionomycin at 1 mg/ml for 16 hr, after which cells were harvested and assayed for luciferase activity.
(D) K562 cells were treated with imatinib and CsA as indicated. After 24 hr, the cells were harvested and lysates subjected to western blot analysis for phosphor-
ylated (p) Bcr-Abl, CrkL, STAT5, and total phosphotyrosine or EIF-4E (loading control).
(E) KBM7 CML cells were treated with imatinib and CsA as in (A) for 48 hr and viable cells were counted.
(F) SUP-B15 Ph+ ALL cells were treated with imatinib and CsA as in (A) for 72 hr and viable cells were counted. Error bars represent ± SD. See also Figure S4.
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KN93 on K562 cell viability are not attributable to decreased
imatinib efflux through inhibition of MDR1.
The effects of the combination of CsA and imatinib on the
viability of a different CML cell line, KBM7, were then assessed
(Figure 3E). CsA at 2.5 and 5 mM showed synergistic elimination
of KBM7 cells in combination with 0.05 mM imatinib. Upon drug
removal and growth for 3 days, a synergistic effect of the drug
combination on long-term viability was evident (Figure S4D).
Given the effectiveness of CsA combined with imatinib in killing
CML cells, we tested whether the same might also apply to
Ph+ ALL cells, which are known to be more refractory to Bcr-
Abl inhibition. We utilized SUP-B15 cells, a cell line established
from a patient with Ph+ B cell ALL. Although neither CsA nor
imatinib had a severe effect, the combination caused synergistic
cell killing (Figure 3F). These results suggest that calcineurin-
NFAT is a promising therapeutic target for CML and Ph+ ALL.
To determine whether the synergism observed with imatinib
and CsA in cell lines extends to primary human tumors, we
treated CD34+ cells isolated from bone marrow of two patients
with CML in chronic phase (CP) with imatinib and/or CsA incolony-forming assays. CsA synergized with imatinib in sup-
pressing colony formation at all doses of imatinib tested in the
‘‘Patient 1’’ sample and at 2 mM IM in the ‘‘Patient 2’’ sample
(Figure 4A; CI values, Table S3). CsA also cooperated with
imatinib in inhibiting proliferation of cells from 2 additional CP
CML samples as measured by an MTS assay (Figure S5).
Thus, CsA is effective at sensitizing primary human Ph+ leukemia
cells to the effects of Bcr-Abl inhibition.
A fraction of CML patients who initially respond to imatinib
develop resistance through mutations in Bcr-Abl that impair
imatinib binding. The three most common mutations observed
in patients are T315I, E255K, and M351T, with the latter two
Bcr-Abl mutants retaining partial sensitivity to imatinib. We
have shown that CsA synergizes with imatinib at a concentration
that only partially inhibit Bcr-Abl (0.1 mM imatinib). To test
whether CsA can sensitize cells that express mutated Bcr-Abl
to the effects of imatinib, Ba/F3 murine pro-B cells were stably
transduced with empty vector, native Bcr-Abl, or Bcr-Abl with
M351T or E255K mutations. As shown in Figure 4B, Ba/F3 cells
without Bcr-Abl (‘‘Vec’’) were unaffected by imatinib at 0.1 mM,
and CsA at 5 mM had only a moderate effect on viability.Cancer Cell 18, 74–87, July 13, 2010 ª2010 Elsevier Inc. 79
Figure 4. CsA Sensitizes Primary CML Cells
and Cells with Imatinib-Resistant Forms of
Bcr-Abl to Imatinib
(A) Colony formation assays were performed on
CD34+ cells purified from bone marrow of two
patients with chronic phase CML in the presence
of imatinib and/or cyclosporine at the indicated
concentrations (increasing CsA concentrations of
0, 1, 2.5, and 5 mM [patient 1] or 0, 2.5, and 5 mM
[patient 2] are indicated by the triangles).
(B) Ba/F3 cells transduced with vector, wild-type
Bcr-Abl, or imatinib-resistant mutant forms of
Bcr-Abl (M351T or E255K) were treated with ima-
tinib and CsA alone or in combination as indicated
(increasing CsA concentrations of 0, 2.5, and 5 mM
are indicated by the triangles) for 72 hr and viable
cells were counted. Error bars represent ± SD.
See also Figure S5.
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exquisitely sensitive to the imatinib/CsA combination, arguing
that CsA synergism with imatinib is Bcr-Abl dependent. CsA
also sensitized imatinib-resistant M351T mutant cells to the
effects of 0.1 mM imatinib and the more resistant E255K cells to
1 mM imatinib, indicating that CsA can sensitize mutant Bcr-Abl
cells to partial inhibitionof Bcr-Abl by imatinib. CsA also enhanced
killing of Ba/F3 vector cells by imatinib (1 mM), suggesting an off-
target effect of imatinib. However, this effect was not comparable
to the dramatic effectof CsA/imatinib on Bcr-Abl nativeor mutant-
expressing cells, enforcing the hypothesis that CsA synergism
with imatinib is predominantly Bcr-Abl dependent.
NFAT Signaling Promotes Survival of Leukemia Cells
upon Bcr-Abl Inhibition
If CsA sensitizes Bcr-Abl+ cells to imatinib-induced cell death
through inhibition of calcineurin and subsequent inhibition of
NFAT, then activation of NFAT should protect cells from imati-
nib-induced death. NFAT-dependent transcription can be acti-
vated by treatment of cells with ionomycin, which elevates levels
of intracellular Ca2+ resulting in activation of calcineurin and80 Cancer Cell 18, 74–87, July 13, 2010 ª2010 Elsevier Inc.NFAT nuclear translocation, and/or the
phorbol ester PMA, which activates
protein kinase C, promoting activation of
NFAT cofactor AP-1. K562 cells were
treated with PMA and ionomycin alone or
in combination for 6 hr followed by treat-
ment with 1 mM imatinib for 48 hr. Treat-
ment with either agent enhanced cell
viability and the combination increased
viability by 2.5-fold after exposure to imati-
nib compared to untreated cells (Fig-
ure 5A). We verified that NFATc1, identified
in our screen as a SLIM, is expressed in
CML cells and that its translocation to the
nucleus is induced by ionomycin in the
presence or absence of PMA (Figure 5B).
To directly assess whether NFAT acti-
vation can protect Ph+ cells from imatinib,
we transduced K562 cells with a retro-virus encoding a constitutively active NFATc1 coexpressed
with GFP (Monticelli and Rao, 2002). Of note, in the absence of
imatinib treatment, these cells are unable to maintain overex-
pression of constitutively active NFATc1 (data not shown), sug-
gesting a negative impact on cell growth. However, imatinib
treatment selects for cells that express NFATc1 (GFP+), resulting
in a 4-fold increase in GFP+ cells relative to untreated cells (trans-
duction efficiency: 1%) with no effect on cells carrying empty
vector (4% GFP with or without imatinib) (Figure 5C). Selection
for constitutive NFAT activity occurred in the presence and
absence of CsA, consistent with complete bypass of the need
for calcineurin activity. Thus, activation of NFAT can provide
a major survival advantage to CML cells upon Bcr-Abl inhibition
with imatinib.
The majority of NFAT transcriptional targets are cytokines,
suggesting that NFAT-driven autocrine cytokine production
may protect Ph+ leukemia cells from Bcr-Abl inhibitor-mediated
cell death. To probe for NFAT-dependent cytokine production by
CML cells, antibody-based cytokine arrays were performed
using conditioned media from untreated K562 cells or K562 cells
treated with CsA for 24 hr. CsA inhibited the production of
Figure 5. NFAT Protects CML Cells from Imatinib-Induced Cell
Death
(A) K562 cells were treated with ionomycin (1 mg/ml) alone or in combination
with PMA (10 ng/ml). After 16 hr, the cells were treated ± 1 mM imatinib for
48 hr as indicated and the number of viable cells was counted.
(B) K562 cells were treated with PMA and/or ionomycin, or CsA for 16 hr and
harvested. Whole cells lysates and nuclear extracts were prepared and sub-
jected to western blotting for NFATc1. The nuclear extract blot was stripped
and reprobed for lamin C as a loading control.
(C) K562 cells were infected with retrovirus expressing GFP alone or constitu-
tively active NFATc1-GFP. Forty-eight hours after infection, the cells were
treated with imatinib at the indicated concentrations and/or CsA (5 mM) for
72 hr and the percentages of viable GFP+ (relative to all viable cells) were deter-
mined with flow cytometry. Error bars represent ± SD.
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IL-4, IFN-g, and TNF-a, whereas other secreted factors not
known to be NFAT-dependent, such as MMP3, TNFRII and
IL-15, remained mostly unchanged (Figure 6A). To examine
whether knockdown of FZD-8 affects cytokine production,
consistent with Wnt/Ca2+ signaling controlling NFAT activity,
we subjected K562 cells expressing shA (negative control) and
shB (FZD-8 knockdown), described in Figure 2, to cytokine array
analysis. Figure 6B shows that FZD-8 knockdown is not the
equivalent of universal calcineurin inhibition with CsA, indicating
that there is some specificity to FZD-8 signaling. However,
several NFAT-dependent cytokines were commonly downregu-
lated upon FZD-8 knockdown, including IL-4 and IFN-g, sup-
porting a role for FZD-8 signaling in regulating NFAT-controlled
transcription of a subset of cytokines.
Given that both CsA treatment and FZD-8 knockdown impair
its production and that it was identified as a SLIM, IL-4 is
a good candidate for a cytokine with a role in maintaining survival
of Ph+ cells upon Bcr-Abl inhibition. We asked whether the IL-4
neutralizing monoclonal antibody 11B11 could sensitize Bcr-
Abl-expressing murine Ba/F3 cells to killing by imatinib. Cytokine
array analysis confirmed that these cells have IL-4 production
that is suppressed by CsA (Figure S6A). Treatment with 11B11
resulted in dramatic dose-dependent cell killing when combined
with imatinib, similar to what was observed with CsA treatment
(Figure 6C). Thus, IL-4 inhibition is sufficient to sensitize Bcr-
Abl+ cells to imatinib. A monoclonal antibody that neutralizes
murine CD4, which is not expressed by B cells, had only
minor effects alone or in combination with imatinib (Figure S6B).
Addition of exogenous murine IL-4 protected the cells from
the effects of imatinib and, in fact, largely reversed the ability
of CsA to sensitize the cells to imatinib (Figure 6D). Because
IL-4 is a target of NFAT, these results reinforce the conclusion
that the observed synergy with CsA and Bcr-Abl inhibitors is
due to calcineurin-NFAT inhibition rather than inhibition of
MDR1.
NFAT Inhibition with CsA Enhances Elimination
of Bcr-Abl+ Leukemia by Dasatinib In Vivo
Finally, we wanted to test whether inhibition of NFAT signaling by
CsA could enhance the ability of a Bcr-Abl inhibitor to eliminate
Ph+ leukemia cells in vivo. Transduction of bone marrow from
ARF/ mice with p185 Bcr-Abl/GFP generates an aggressive
B cell acute lymphoblastic leukemia (B-ALL), providing a trac-
table model that is reflective of human Ph+ ALL (Williams et al.,
2007). The therapeutic response observed with dasatinib in
this model mirrors that seen in patients: although dasatinib
reduces leukemic burden, a significant number of dasatinib-
refractory leukemia cells are maintained and the disease often
relapses with resistance mutations in Bcr-Abl (Williams and
Sherr, 2008). To test the effects of dasatinib combined with
CsA while using this model, we inoculated mice with 5 3 105
ARF/ p185 B-ALL cells and after 3 days to allow engraftment,
we treated mice with vehicle, CsA alone, dasatinib alone, or
dasatinib and CsA in combination. An initial experiment, with
therapy up to day 96, showed that mice treated with vehicle or
with CsA alone succumbed to leukemia on day 10, whereas
treatment with dasatinib alone and dasatinib/CsA resulted in
50% and 100% leukemia-free survival, respectively (Figure S7).Cancer Cell 18, 74–87, July 13, 2010 ª2010 Elsevier Inc. 81
Figure 6. IL-4 Production Is NFAT and FZD-8 Dependent and Protects Ph+ Cells from Imatinib
(A) Conditioned media from K562 cells treated ± CsA at 5mM was used for cytokine array analysis. Cytokines that were consistently detectable are labeled.
(B) Conditioned media from K562 cells expressing FZD-8 shA (no knockdown) or shB (FZD-8 knockdown) was prepared and used for cytokine array analysis.
(C) Ba/F3 cells expressing Bcr-Abl (described in Figure 4) were treated with imatinib and neutralizing IL-4 antibody (11B11) alone or in combination (increasing
11B11 concentrations of 0, 25, 50, and 100 mg/ml are indicated by the triangles) for 72 hr and viable cells were counted.
(D) Ba/F3 cells expressing Bcr-Abl were treated with the indicated concentrations of recombinant murine IL-4 together with 0.1 mM imatinib and/or 5 mM CsA for
72 hr and viable cells were counted. Error bars represent ± SD. See also Figure S6.
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Figure 7. CsA Enhances Elimination of Ph+ ALL Cells by Dasatinib In Vivo
C57BL/6 mice were inoculated intravenously with 5 3 105 ARF/ p185 Bcr-Abl/GFP B-ALL cells. After 3 days, groups of mice were treated once daily by oral
gavage with vehicle (80 mM citric acid [pH 3.1]; n = 5), CsA (25 mg/kg; n = 5), dasatinib (20 mg/kg; n = 10), or dasatinib and CsA combined (n = 10) up to day 52
postinoculation.
(A) After 3 days of therapy, peripheral blood from all mice was immunostained for B220 and Mac-1 and analyzed by flow cytometry. The percentage of GFP+ cells
in the B-lineage (B220+, Mac-1) population was determined and plotted.
(B) Peripheral blood was taken on the indicated days and analyzed as in (A) and plotted over time. The limit of detection of GFP in peripheral blood, based on
analyses of blood from control C57Bl/6 mice is 0.1%.
(C) Kaplan-Meier curve showing survival of mice receiving the indicated therapy. Mice were sacrificed when moribund, and all showed clear evidence of leukemia
in blood, bone marrow and spleen. See also Figure S7.
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leukemic burden in the peripheral blood was assessed by flow
cytometry after 3 days of therapy. This analysis found that
whereas CsA by itself had no significant effect, CsA in combina-
tion with dasatinib was far more effective than dasatinib alone at
rapid elimination of Bcr-Abl+ leukemic B cells (GFP+, B220+,
Mac1) from the blood (Figure 7A). Weekly analysis of peripheral
blood showed that GFP+ B cells remained at near undetectable
levels in mice receiving dasatinib/CsA, whereas leukemic cells
eventually rose to high levels in mice receiving dasatinib alone
(Figure 7B). Mice receiving vehicle or CsA alone were moribund
and sacrificed on day 10 (Figure 7C). Postmortem analysis
showed extensive leukemia in the blood, bone marrow and
spleen (not shown). By day 52, eight of ten mice receiving dasa-
tinib alone had succumbed to leukemia and therapy was halted
to determine if leukemia had been eradicated in the surviving
mice. The two remaining dasatinib-treated mice succumbed to
leukemia within 16 days, whereas all ten of the dasatinib/CsA
treated mice remained healthy up to day 119, when the experi-ment was terminated (Figure 7C). Postmortem analysis of these
mice revealed no GFP+ cells in the blood, bone marrow, and
spleen, and white blood cell counts were normal (not shown).
Thus, under conditions where dasatinib as monotherapy was
largely ineffective, adjuvant therapy with CsA resulted in
complete eradication of Bcr-Abl+ leukemia.
Taken together, our data indicate that signaling through the
Wnt/Ca2+/NFAT pathway plays a role in maintaining survival of
Ph+ leukemia cells upon Bcr-Abl inhibition and suggests that
targeting this pathway in tandem with Bcr-Abl represents an
effective therapeutic strategy for treatment of CML and Ph+ ALL.
DISCUSSION
Although the success of imatinib in patients with chronic phase
CML has revolutionized the treatment of this disease, relapses
remain common among patients with advanced CML or Ph+
ALL, and high failure rates persist with second-line dasatinib
and nilotinib therapy (Milone and Enrico, 2009; Quintas-CardamaCancer Cell 18, 74–87, July 13, 2010 ª2010 Elsevier Inc. 83
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tyrosine kinase inhibitor-based targeted therapy in other types
of cancer, which is likely due to the increased genetic complexity
of these diseases. Because imatinib therapy has rarely proven to
be curative, eradication of Ph+ leukemias will probably require
targeting other gene products in addition to Bcr-Abl.
We applied a large-scale RNAi screening approach to identify
genetic pathways that could sensitize blast crisis CML cells to
Bcr-Abl inhibition by imatinib. Our screen identified numerous
components of a noncanonical Wnt/Ca2+/NFAT pathway as
being synthetic lethal with imatinib, suggesting this pathway
plays a role in maintenance of Bcr-Abl+ leukemia cells despite
Bcr-Abl inhibition. These studies highlight the strength of an
unbiased synthetic lethal screen: the Wnt/Ca2+ pathway has
not previously been implicated in CML or Ph+ ALL pathogenesis,
and analyses of gene expression changes that accompany CML
progression to advanced phases does not reveal significantly
altered expression of this pathway during CML evolution (Radich
et al., 2006). A pathway does not necessarily need to be differen-
tially expressed or mutationally deregulated in a cancer to
contribute to resistance to a therapy that the cancer did not
evolve to endure. An unbiased screen provides a unique oppor-
tunity to uncover such pathways.
The Wnt/Ca2+/NFAT pathway is largely uncharacterized in
mammalian cells, with most studies performed in Xenopus and
zebrafish, and its role in human cancer remains controversial.
Some studies support a role for noncanonical Wnt signaling as
tumor-suppressive, while others indicate a role in promoting
tumorigenesis (reviewed in Pukrop and Binder, 2008). Our data
strongly support a role for the Wnt receptor FZD-8 as a mediator
of Wnt/Ca2+/NFAT signaling in CML, given that FZD-8 knock-
down causes impaired NFAT activity and impaired production
of NFAT-regulated cytokines. FZD-8 is a poorly studied receptor
that has not previously been shown to be involved in Wnt/Ca2+
signaling. Ectopic overexpression studies showed that FZD-8
is capable of activating b-catenin-dependent signaling when
co-expressed with the canonical coreceptor LRP6 (Liu et al.,
2005). However, studies performed in Xenopus implicate FZD-8
in b-catenin-independent Wnt signaling (Wallingford et al.,
2001). Whether a given FZD receptor signals through canonical
or noncanonical pathways may be dependent on what corecep-
tor is utilized (Cadigan and Liu, 2006).
The Wnt/Ca2+/NFAT pathway has multiple branches that lead
to activation of PDE, CaMKII, calcineurin and PKC. Given that
these enzymes are not known to have shared substrates, it
was somewhat surprising that all components of this pathway
were identified in our screen. However, multiple components
of this pathway can converge on activation of NFAT. We provide
evidence that inhibition of FZD-8, CaMKII and calcineurin all
impair NFAT activity, which correlates with an increased sensi-
tivity to imatinib. While calcineurin is known to control nuclear
translocation of NFAT, the precise role of CaMKII in NFAT activa-
tion is less clear. CaMKII has been shown to activate the NFAT-
cooperative transcription factor NK-kB in T cells through direct
phosphorylation of CARMA1 (Ishiguro et al., 2006). Exactly
how CaMKII and other components of this pathway impinge
upon NFAT-dependent transcription in Ph+ leukemia cells
remains to be established. Nonetheless, our data strongly argue
that NFAT plays a critical role in survival of Ph+ leukemia cells84 Cancer Cell 18, 74–87, July 13, 2010 ª2010 Elsevier Inc.upon Bcr-Abl inhibition. This role is best evidenced by our find-
ings that overexpression of constitutively active NFATc1
protects CML cells from imatinib-mediated killing and that
CsA sensitizes multiple types of Ph+ cells to Bcr-Abl inhibition.
In light of recent studies implicating calcineurin-NFAT signaling
in survival of T cell acute lymphoblastic leukemias (Medyouf
et al., 2007), our studies support a perhaps underappreciated
role of NFAT in hematopoietic and other types of cancer, since
NFAT activation is implicated in tumors of epithelial cell origin
as well (Medyouf and Ghysdael, 2008).
Much of the data presented in this report relies on calcineurin-
NFAT inhibition by CsA. Given the importance of NFAT for T cell
development and function, CsA is commonly utilized in the clinic
as an effective immunosuppressive agent after organ transplan-
tation. However, CsA is also known to inhibit p-glycoprotein
encoded by the multiple drug resistance gene MDR1. Yokota
et al. tested INNO-406, an experimental Bcr-Abl inhibitor, in
combination with CsA in a mouse model of Ph+ CNS leukemia
where it enhanced INNO-406-mediated elimination of Bcr-Abl-
expressing Ba/F3 cells from the brain (Yokota et al., 2007). Their
explanation of these results was that CsA acts as a p-glycopro-
tein inhibitor to decrease efflux of INNO-406 at the blood-brain
barrier, although CsA only moderately enhanced INNO-406
levels in the brain. Based on our data, we would argue that their
observed effects are more likely due to CsA-mediated calcineurin
inhibition synergizing with Bcr-Abl inhibition. In this study, we
found no significant effect of CsA on the Bcr-Abl inhibitory activity
of imatinib, inconsistent with a role for p-glycoprotein in efflux of
imatinib from CML cells. This contention is further supported by
the observations that MDR1 deletion does not enhance sensi-
tivity of CML cells to imatinib in vivo (Zong et al., 2005) and artifi-
cial overexpression of p-glycoprotein is necessary to enhance
imatinib efflux in K562 cells (Illmer et al., 2004).
Our data support a scenario whereby enhanced NFAT activity
in Ph+ cells, mediated by noncanonical Wnt/Ca2+ signaling,
increases autocrine NFAT-dependent cytokine production that
provides compensatory survival signaling upon exposure to
imatinib. Cytokine signaling is increasingly found to have roles
in multiple types of leukemia (Van Etten, 2007), and the nonca-
nonical ligand Wnt5a has been shown to play a role in upregula-
tion of multiple cytokines in hematopoietic cells (Blumenthal
et al., 2006; Pereira et al., 2008). We found that IL-4 was
commonly downregulated by both FZD-8 and calcineurin-
NFAT inhibition, which sensitized Ph+ leukemia cells to Bcr-Abl
inhibition. It is intriguing that autocrine IL-4 production was
recently shown to maintain survival of colon cancer stem cells
upon treatment with chemotherapeutics (Francipane et al.,
2008; Todaro et al., 2007), implicating IL-4 signaling as a general
mediator of cell survival in the face of therapeutic stress. Further-
more, deletion of the cytokine receptor common g chain, through
which IL-4 signals, restores the sensitivity of imatinib-refractory
Bcr-Abl+ ARF/ ALL cells to imatinib in vivo (Williams et al.,
2007). In vivo, stromal cells are a likely source of prosurvival
cytokines for leukemia cells. However, given that cytokine
gene transcription is often NFAT dependent, inhibiting calci-
neurin-NFAT should also severely impair cytokine-mediated
survival signaling coming from paracrine sources.
The possibility that prosurvival cues might come from the
environment of Ph+ leukemia cells necessitated the testing of
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Ph+ leukemia. We chose to test our therapeutic approach in
a model of Ph+ ALL, because this disease is refractory to therapy
with Bcr-Abl inhibitors alone. Treatment of mice bearing Bcr-
Abl+ ARF/ ALL cells with dasatinib has been shown to be inef-
fective in completely eliminating leukemia cells, resulting in the
rapid appearance of dasatinib resistance (Williams and Sherr,
2008). Our in vivo results show that dasatinib combined with
CsA therapy can be quite successful in eradication of Ph+
leukemia that is refractory to dasatinib therapy alone. These
results could have important implications for improving clinical
responses to Bcr-Abl inhibitors in Ph+ ALL and possibly
advanced CML.
The results presented in this report strongly support the ther-
apeutic strategy of combining Bcr-Abl inhibition with inhibition of
NFAT by CsA or other NFAT-inhibitory approaches. Given that
CsA has long been in clinical use, its pharmacodynamics and
side effects are well understood. Thus, clinical trials exploring
the efficacy of CsA combined with Bcr-Abl inhibitors for the
treatment of Bcr-Abl inhibitor-refractory Ph+ leukemias may be
warranted. The therapeutic efficacy of inhibiting specific NFAT
targets, such as IL-4, also deserves exploration. Finally, our
synthetic lethal RNAi-based screen, which allowed for the rapid
identification of adjuvant drug targets in Bcr-Abl+ leukemia, may
serve as an efficient model for the discovery of combination
therapies for the treatment of various other types of cancer.
EXPERIMENTAL PROCEDURES
ShRNA Screen and Analysis
A total of 1 3 107 K562 cells were transduced with 1 3 106 ifu of the lentiviral
human 50K shRNA library (GeneNet, SBI) using standard methods. Two days
after infection, cells were subjected to selection in puromycin (2.5 mg/ml) for
a period of 2 weeks. The cells were then divided into six groups of 13 107 cells:
three were left untreated, and the other three were treated with imatinib at 1 mM
for 72 hr and were cultured for an additional week. Total RNA was isolated from
each group using Trizol reagent (Invitrogen) and reverse transcribed with
M-MLV reverse transcriptase (Epicenter). shRNA sequences were PCR ampli-
fied and labeled with biotin according to the manufacturer’s instructions. Then,
15 mg biotin-labeled PCR products were used for hybridization to microarrays
(Affymetrix, HG-U133+ 2.0) and analysis of signal intensities was performed
with GeneNet software (SBI). See the Supplemental Information for details of
the data normalization and determination of significant changes.
Cell Culture and Generation of Cell Lines
K562 and KBM7 cells (a gift from M. Beran, MD Anderson) were cultured in
Iscove’s modified Dulbecco’s medium/10% fetal bovine serum (FBS). For
generation of shRNA-expressing cell lines, lentivirus production from pLKO.1
constructs and transduction were performed as described previously (Porter
and DeGregori, 2008) and cells were selected and maintained in puromycin
(2.5 mg/ml). SUP-B15 cells were cultured in RPMI 1640 medium/20% FBS
with 5mM b-mercaptoethanol. Ba/F3 cells were cultured in RPMI 1640
medium/10% FBS and 15% WEHI3 conditioned medium (WCM). Ba/F3 cell
lines expressing Bcr-Abl and mutated derivatives (gifts of B. Deininger, OHSU)
were generated by retroviral transduction using MSCV-ires-GFP constructs as
previously described (Marusyk et al., 2007); GFP+ cells were sorted and main-
tained in media lacking WCM. Bcr-Abl+ ARF/ ALL cells were generated as
previously described (Williams et al., 2007) and were cultured in RPMI 1640
medium/10% FBS and 2x L-glutamine prior to inoculation into mice.
Quantitative Real-Time PCR
Quantitative real-time PCR was performed with the TaqMan method as
described previously (Shapiro et al., 2006). Primer and probe sequences are
provided in the Supplemental Information.Cell Viability Assays
Cells were seeded at 1 3 105/ml in triplicate wells of 24-well tissue culture
plates. Where indicated, the cells (immediately after seeding) were treated
with drug for a period of 48–72 hr. After or during treatment, a sample of cells
from each well was stained with PI (10 mg/ml) and viable cells (PI) were
counted with a flow cytometer (Quanta SC, Beckman Coulter). For some
experiments, the number of GFP+ viable (PI) was counted in the same
manner. The results from two independent experiments were combined and
plotted with the standard deviation (SD).
Colony-Forming Assays
A total of 5 3 104 CD34+ cells from primary CP CML samples were plated in
0.9% MethoCult (Stem Cell Technologies) supplemented with 30% FBS, 1%
bovine serum albumin, 2 mM L-glutamine and rhIL-3 (100 ng/ml), and in the
presence of the indicated drug combinations. Colony numbers were scored
14 days after plating. The frozen nonidentifiable bone marrow patient speci-
mens were obtained with informed consent from the OSU Leukemia Tissue
Bank, Columbus OH, and all of the performed experiments were approved
by The OSU Institutional Review Board.
Western Blotting
Nuclear extracts were prepared with the protocol described at http://
www.protocol-online.org/cgi-bin/prot/view_cache.cgi?ID=2701. Preparation
of whole cell lysates and western blotting were performed as previously
described (Shapiro et al., 2006). Antibodies utilized were anti-NFATc1 (7A6,
Santa Cruz), anti-lamin C (636, Santa Cruz), anti-b-catenin (clone14, BD Trans-
duction Laboratories), anti-a-tubulin (DM1A; MeoMarkers), and antiphospho-
tyrosine (4G10; Millipore). Phosphospecific antibodies to c-Abl (#2681), CrkL
(#3181) and Stat5 (#9351), and anti-eIF4E (#9742) were from Cell Signaling
Technology.
Reporter Assays
K562 cells were coinfected with 10 infectious units (ifu)/cell of adenovirus
containing the 9XNFAT-luciferase reporter plus adenovirus expressing GFP.
Forty-eight hours after infection, a sample of cells was analyzed by flow cytom-
etry to determine the number of viable (PI) GFP+ cells and lysates were sub-
jected to standard firefly luciferase assays (Promega). Luciferase values were
normalized to the number of GFP+ cells. Results shown are from two indepen-
dent experiments; error bars represent SD.
Cytokine Assays
Conditioned media was generated by incubating 2 3 106 cells in 2 ml low
serum (0.2% FBS) media for 24 hr, in the presence or absence of CsA, as indi-
cated. Conditioned media was incubated on antibody-based cytokine arrays
(Panomics, Human Array 3.0) for 16 hr at 4C. Detection was performed
according to the manufacturer’s instructions. Results are representative of
two independent experiments.
Mice
Female C57BL/6 mice (6–10 weeks old) from the National Cancer Institute
were utilized for experiments. Dasatinib was prepared by dissolving in
80 mM citric acid (pH 2.1) daily for oral gavage. Cyclosporin A (Neoral; Novar-
tis) was added directly to vehicle or dasatinib preparation just prior to gavage.
All mouse experiments were approved by the University of Colorado Denver
IACUC.
Flow Cytometry Analysis
Flow cytometry was performed as previously described (Porter and
DeGregori, 2008). Antibodies utilized for cell surface staining were anti-mouse
B220-APC, anti-mouse B220-PE, and anti-mouse Mac1-PE-Cy7 (all from
eBioscience). Statistical analysis of results was performed using Prism 4
software (GraphPad). Unpaired two-tailed t tests were used for determining
statistical significance between two groups.
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